Translational pain research: Evaluating analgesic effect in experimental visceral pain models

World Journal of Gastroenterology

Volumn 15, Issue 2, 2009, Pages 177-181

  Olesen, Anne Estrup ^a,b   Andresen, Trine ^a,b   Christrup, Lona Louring ^c   Upton, Richard N ^d  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Analgesics; Pharmacodynamics; Pharmacokinetics; Visceral pain

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; IMIPRAMINE; KAPPA OPIATE RECEPTOR; KETAMINE; MORPHINE; MU OPIATE RECEPTOR AGONIST; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE DERIVATIVE; OPIATE RECEPTOR; OXYCODONE; PLACEBO; SEDATIVE AGENT;

ANALGESIA; ANALGESIC ACTIVITY; AROUSAL; ARTICLE; BLOOD BRAIN BARRIER; CORRELATIONAL STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; ELECTROENCEPHALOGRAPHY; ESOPHAGUS PAIN; HUMAN; MEDICAL RESEARCH; MYALGIA; NEUROPHYSIOLOGY; NOCICEPTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN ASSESSMENT; PATHOPHYSIOLOGY; VISCERAL PAIN; VOLUNTEER;

EID: 59249109220     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.177     Document Type: Article

References (33)

1. Konig HH, Bernert S, Angermeyer MC. [Health Status of the German population: results of a representative survey using the EuroQol questionnaire] Gesundheitswesen 2005; 67: 173-182
2. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283: 1710-1714
3. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 38-45
4. Strigo IA, Duncan GH, Bushnell MC, Boivin M, Wainer I, Rodriguez Rosas ME, Persson J. The effects of racemic ketamine on painful stimulation of skin and viscera in human subjects. Pain 2005; 113: 255-264
5. Willert RP, Woolf CJ, Hobson AR, Delaney C, Thompson DG, Aziz Q. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 2004; 126: 683-692
6. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-813
7. Gorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-G466
8. Staahl C, Reddy H, Andersen SD, Arendt-Nielsen L, Drewes AM. Multi-modal and tissue-differentiated experimental pain assessment: reproducibility of a new concept for assessment of analgesics. Basic Clin Pharmacol Toxicol 2006; 98: 201-211
9. Drewes AM, Gregersen H, Arendt-Nielsen L. Experimental pain in gastroenterology: a reappraisal of human studies. Scand J Gastroenterol 2003; 38: 1115-1130
10. Drewes AM, Schipper KP, Dimcevski G, Petersen P, Andersen OK, Gregersen H, Arendt-Nielsen L. Multi-modal induction and assessment of allodynia and hyperalgesia in the human oesophagus. Eur J Pain 2003; 7: 539-549
11. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29: S90-S103
12. Upton RN, Ludbrook GL, Gray EC, Grant C. The cerebral pharmacokinetics of meperidine and alfentanil in conscious sheep. Anesthesiology 1997; 86: 1317-1325
13. Upton RN, Ludbrook GL, Martinez AM, Grant C, Milne RW. Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions. Br J Anaesth 2003; 90: 750-758
14. Upton RN, Ludbrook G. A physiologically based, recirculatory model of the kinetics and dynamics of propofol in man. Anesthesiology 2005; 103: 344-352
15. Villesen HH, Foster DJ, Upton RN, Somogyi AA, Martinez A, Grant C. Cerebral kinetics of oxycodone in conscious sheep. J Pharm Sci 2006; 95: 1666-1676
16. Poyhia R, Hynynen M, Seppala T, Roine RO, Verkkala K, Olkkola KT. Pharmacodynamics and pharmacokinetics of high-dose oxycodone infusion during and after coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2004; 18: 748-754
17. Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, Arendt-Nielsen L, Drewes AM. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol 2008; 48: 619-631
18. Christrup LL, Foster D, Popper LD, Troen T, Upton R. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 2008; 30: 469-481
19. Foster D, Upton R, Christrup L, Popper L. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 2008; 42: 1380-1387
20. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 1998; 284: 1095-1103
21. Groenendaal D, Freijer J, de Mik D, Bouw MR, Danhof M, de Lange EC. Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br J Pharmacol 2007; 151: 713-720
22. Groenendaal D, Freijer J, Rosier A, de Mik D, Nicholls G, Hersey A, Ayrton AD, Danhof M, de Lange EC. Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. Eur J Pharm Sci 2008; 34: 149-163
23. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461-479
24. Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006; 123: 28-36
25. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 383-394
26. Upton RN, Semple TJ, Macintyre PE. Pharmacokinetic optimisation of opioid treatment in acute pain therapy. Clin Pharmacokinet 1997; 33: 225-244
27. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92: 1392-1399
28. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997; 73: 151-157
29. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998; 285: 707-715
30. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003; 101: 89-95
31. Schulte H, Graven-Nielsen T, Sollevi A, Jansson Y, Arendt-Nielsen L, Segerdahl M. Pharmacological modulation of experimental phasic and tonic muscle pain by morphine, alfentanil and ketamine in healthy volunteers. Acta Anaesthesiol Scand 2003; 47: 1020-1030
32. Nie H, Arendt-Nielsen L, Andersen H, Graven-Nielsen T. Temporal summation of pain evoked by mechanical stimulation in deep and superficial tissue. J Pain 2005; 6: 348-355
33. Upton RN. Cerebral uptake of drugs in humans. Clin Exp Pharmacol Physiol 2007; 34: 695-701